Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45).

Perl AL, O'Connor CM, Fa P, Mayca Pozo F, Zhang J, Zhang Y, Narla G.

J Biol Chem. 2019 Sep 27. pii: jbc.RA119.010432. doi: 10.1074/jbc.RA119.010432. [Epub ahead of print]

2.

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.

O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G.

Oncogene. 2019 Sep 20. doi: 10.1038/s41388-019-1012-2. [Epub ahead of print]

PMID:
31541192
3.

CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation.

Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA.

Cancer Discov. 2019 Aug 29. pii: CD-19-0189. doi: 10.1158/2159-8290.CD-19-0189. [Epub ahead of print]

PMID:
31466944
4.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
5.

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4.

PMID:
31164413
6.

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.

Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G.

Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29.

PMID:
31142515
7.

Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.

Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, Hawke DH, Felsher D, Narla G, Lu Z, Lee RT.

Sci Rep. 2019 Apr 23;9(1):6428. doi: 10.1038/s41598-019-41444-2.

8.

Lulling the Cancer Cell into an Eternal Sleep.

Farrington CC, Narla G.

Cancer Res. 2019 Apr 15;79(8):1756-1757. doi: 10.1158/0008-5472.CAN-19-0853.

PMID:
30987978
9.

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G.

JCI Insight. 2019 Feb 21;4(4). pii: 125693. doi: 10.1172/jci.insight.125693. eCollection 2019 Feb 21.

10.

Protein phosphatase 2A Aα regulates Aβ protein expression and stability.

O'Connor CM, Hoffa MT, Taylor SE, Avelar RA, Narla G.

J Biol Chem. 2019 Apr 12;294(15):5923-5934. doi: 10.1074/jbc.RA119.007593. Epub 2019 Feb 22.

PMID:
30796164
11.

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE.

J Clin Invest. 2019 Mar 4;130:1641-1653. doi: 10.1172/JCI123049. eCollection 2019 Mar 4.

12.

Targeting PP2A in cancer: Combination therapies.

Mazhar S, Taylor SE, Sangodkar J, Narla G.

Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Review.

PMID:
30401535
13.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.

PMID:
30389701
14.

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.

Noto FK, Adjan-Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, DiFeo A, Crawford J, Narla G, Jamling TY.

Mol Cancer Ther. 2018 Nov;17(11):2481-2489. doi: 10.1158/1535-7163.MCT-18-0156. Epub 2018 Sep 11.

PMID:
30206106
15.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.

PMID:
30021885
16.

The impact of phosphatases on proliferative and survival signaling in cancer.

Narla G, Sangodkar J, Ryder CB.

Cell Mol Life Sci. 2018 Aug;75(15):2695-2718. doi: 10.1007/s00018-018-2826-8. Epub 2018 May 3. Review.

17.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

18.

Specificity of research antibodies: "trust is good, validation is better".

Ogris E, Sontag E, Wadzinski B, Narla G.

Hum Pathol. 2018 Feb;72:199-201. doi: 10.1016/j.humpath.2017.12.003. Epub 2017 Dec 13. No abstract available.

PMID:
29247663
19.

Therapeutic targeting of PP2A.

O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G.

Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Review.

20.

Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.

Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR.

Proteomics. 2017 Nov;17(22). doi: 10.1002/pmic.201700214. Epub 2017 Oct 25. Erratum in: Proteomics. 2018 Dec;18(24):e1870214.

PMID:
28961369
21.

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G.

J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.

22.

The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination.

Laitman BM, Asp L, Mariani JN, Zhang J, Liu J, Sawai S, Chapouly C, Horng S, Kramer EG, Mitiku N, Loo H, Burlant N, Pedre X, Hara Y, Nudelman G, Zaslavsky E, Lee YM, Braun DA, Lu QR, Narla G, Raine CS, Friedman SL, Casaccia P, John GR.

PLoS Biol. 2016 May 23;14(5):e1002467. doi: 10.1371/journal.pbio.1002467. eCollection 2016 May.

23.

Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].

Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Dec 1;23(23):7487. doi: 10.1016/j.bmc.2015.11.002. Epub 2015 Nov 9. No abstract available.

PMID:
28290285
24.

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G.

FEBS J. 2016 Mar;283(6):1004-24. doi: 10.1111/febs.13573. Epub 2015 Nov 14. Review.

25.

Reengineered tricyclic anti-cancer agents.

Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. doi: 10.1016/j.bmc.2015.07.007. Epub 2015 Sep 11.

PMID:
26372073
26.

Krüppel-like factor 6 regulates mitochondrial function in the kidney.

Mallipattu SK, Horne SJ, D'Agati V, Narla G, Liu R, Frohman MA, Dickman K, Chen EY, Ma'ayan A, Bialkowska AB, Ghaleb AM, Nandan MO, Jain MK, Daehn I, Chuang PY, Yang VW, He JC.

J Clin Invest. 2015 Mar 2;125(3):1347-61. doi: 10.1172/JCI77084. Epub 2015 Feb 17.

27.

Bisphosphonates inactivate human EGFRs to exert antitumor actions.

Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, Latif Y, Mujtaba S, Epstein S, Davies TF, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17989-94. doi: 10.1073/pnas.1421410111. Epub 2014 Dec 1.

28.

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, Mujtaba S, Galsky M, Gomez J, Epstein S, Buettner C, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000. doi: 10.1073/pnas.1421422111. Epub 2014 Dec 1.

29.

IKKα negatively regulates ASC-dependent inflammasome activation.

Martin BN, Wang C, Willette-Brown J, Herjan T, Gulen MF, Zhou H, Bulek K, Franchi L, Sato T, Alnemri ES, Narla G, Zhong XP, Thomas J, Klinman D, Fitzgerald KA, Karin M, Nuñez G, Dubyak G, Hu Y, Li X.

Nat Commun. 2014 Sep 30;5:4977. doi: 10.1038/ncomms5977.

30.

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR.

Mol Cancer Ther. 2014 Sep;13(9):2203-14. doi: 10.1158/1535-7163.MCT-14-0013. Epub 2014 Jul 15.

31.

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.

Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, DiFeo A.

Nat Commun. 2014;5:2977. doi: 10.1038/ncomms3977.

32.

Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization.

Date D, Das R, Narla G, Simon DI, Jain MK, Mahabeleshwar GH.

J Biol Chem. 2014 Apr 11;289(15):10318-29. doi: 10.1074/jbc.M113.526749. Epub 2014 Jan 2.

33.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

34.

Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.

Das TK, Sangodkar J, Negre N, Narla G, Cagan RL.

Oncogene. 2013 Jun 27;32(26):3184-97. doi: 10.1038/onc.2012.326. Epub 2012 Aug 13.

35.

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G.

J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1.

36.

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL.

Hepatology. 2012 Oct;56(4):1361-70. doi: 10.1002/hep.25810. Epub 2012 Aug 27.

37.

Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation.

Mallipattu SK, Liu R, Zheng F, Narla G, Ma'ayan A, Dikman S, Jain MK, Saleem M, D'Agati V, Klotman P, Chuang PY, He JC.

J Biol Chem. 2012 Jun 1;287(23):19122-35. doi: 10.1074/jbc.M112.345983. Epub 2012 Apr 9.

38.

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.

Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL.

Hepatology. 2011 Aug;54(2):522-31. doi: 10.1002/hep.24413. Epub 2011 Jun 26. Erratum in: Hepatology. 2011 Dec;54(6):2280.

39.

Lung adenocarcinoma: lessons in translation from bench to bedside.

Sangodkar J, Katz S, Melville H, Narla G.

Mt Sinai J Med. 2010 Nov-Dec;77(6):597-605. doi: 10.1002/msj.20226. Review.

PMID:
21105123
40.

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression.

Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB.

Dig Dis Sci. 2011 Feb;56(2):406-16. doi: 10.1007/s10620-010-1296-0. Epub 2010 Jun 19.

41.

Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma.

Tchirkov A, Sapin V, Marceau G, Chautard E, Narla G, Veronese L, Friedman S, Khalil T, Vago P, Kemeny JL, Verrelle P.

Clin Chem Lab Med. 2010 Aug;48(8):1167-70. doi: 10.1515/CCLM.2010.219.

PMID:
20545576
42.

Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene.

Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, Walsh M, Friedman SL.

FEBS Lett. 2010 Mar 5;584(5):1006-10. doi: 10.1016/j.febslet.2010.01.049. Epub 2010 Jan 30.

43.

Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

DiFeo A, Narla G, Martignetti JA.

Mt Sinai J Med. 2009 Dec;76(6):557-66. doi: 10.1002/msj.20150. Review.

44.

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA.

Cancer Res. 2009 Jun 1;69(11):4733-41. doi: 10.1158/0008-5472.CAN-08-4282. Epub 2009 May 12.

45.

Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.

Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC.

Int J Cancer. 2009 Aug 15;125(4):774-82. doi: 10.1002/ijc.24325. Erratum in: Int J Cancer. 2009 Oct 15;125(8):1995.

46.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.

47.

Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G.

Eur J Cancer. 2009 Mar;45(4):666-76. doi: 10.1016/j.ejca.2008.11.009. Epub 2008 Dec 26.

48.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
49.

TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction.

Botella LM, Sanz-Rodriguez F, Komi Y, Fernandez-L A, Varela E, Garrido-Martin EM, Narla G, Friedman SL, Kojima S.

Biochem J. 2009 Apr 15;419(2):485-95. doi: 10.1042/BJ20081434.

50.

Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer.

Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL.

Eur J Cancer. 2008 Sep;44(13):1895-903. doi: 10.1016/j.ejca.2008.06.030. Epub 2008 Aug 6.

Supplemental Content

Support Center